Patients
Consecutive patients with obstructive HCM planned for radiofrequency AF CA between January 2016 and March 2020 were enrolled, and prospectively studied. Patient demographics, medical history, medications, echocardiographic data [interventricular septum (IVS) thickness, left ventricular end-diastolic diameter (LVEDD), LA diameter, LA volume, left ventricular outflow tract (LVOT) gradient, and left ventricular ejection fraction (LVEF)], and procedural data were collected in all cases. HCM patients were propensity score (PS) matched to patients without HCM (non-HCM) who underwent AF CA, and served as control group.
The diagnosis of HCM was based on 2‐dimensional echocardiography and defined by a wall thickness ≥15 mm or ≥13mm in patients with a documented family history of HCM that is not explained by another cardiac or systemic disease capable of producing the magnitude of hypertrophy.11 LVOT obstruction was defined as an outflow tract gradient ≥30 mmHg at rest or during Valsalva maneuver, standing or exercise.11
The institutional ethics committee approved the study protocol, and written informed consent was obtained from all patients.